The themes Nexalin Technology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
De omzetaandelen zijn schattingen voor year ended 2025-12-31, geen cijfers uit een ingediend rapport.
Gen-1
An earlier cranial electrotherapy stimulation device used by medical professionals. Nexalin continues to service previously sold or leased devices but has paused new United States sales and marketing.
Gen-2 SYNC
A clinical-use device that delivers Nexalin’s newer 15-milliamp electrical waveform. It is under United States regulatory review and clinical development.
Gen-3 HALO
A headset being studied for physician-supervised treatment at home. A United States clinical trial for insomnia is underway.
Nexalin NeuroCare
Software for remote patient monitoring, doctors’ clinical workflows, collection of clinical data and virtual care.
Electrodes and patient cables
Replacement treatment components sold to medical providers using Nexalin devices.
Nexalin develops devices that use electrical signals delivered through electrodes on the head to stimulate the brain. Its SYNC device is intended for clinical use, while its HALO headset is being studied for physician-supervised home use; a clinical trial for insomnia is underway. Nexalin also develops software for doctors to oversee patients remotely, manage care and collect clinical information.
Gebouwd uit de eigen deponeringen van Nexalin Technology, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
US$ 1,48-0,7%slot 13 nov
Cijfers tot en met 30 september 2026, uit de 10-Q ingediend op 12 november 2026
Nexalin sells brain-stimulation devices and treatment supplies to medical clinics, and collects licensing fees on older devices already in use.
Grade F-
De balk onder de koers toont het cijfer op elke datum, alleen gebaseerd op de stukken die toen al openbaar waren.
Toont 2 van 15 kwartalen van de cijferhistorie van Nexalin Technology, Inc.. De andere 13 lopen terug tot mei 2023.